- Page 1 and 2: Clinical Manual for Management of t
- Page 3 and 4: Table of Contents Clinical Manual f
- Page 5 and 6: Clinical Manual for Management of t
- Page 7 and 8: Preface—About this Manual | Clini
- Page 9: Previous Editions Atlanta Contribut
- Page 12 and 13: ♦ ♦ ♦ ♦ ♦ | Clinical Manu
- Page 14 and 15: 1-2 | Clinical Manual for Managemen
- Page 16 and 17: 1-4 | Clinical Manual for Managemen
- Page 18 and 19: 1-6 | Clinical Manual for Managemen
- Page 20 and 21: 1-8 | Clinical Manual for Managemen
- Page 23 and 24: Initial Physical Examination Backgr
- Page 25 and 26: Genitals/Rectum • Inspect the gen
- Page 27 and 28: Initial and Interim Laboratory and
- Page 29 and 30: Section 1—Testing and Assessment
- Page 31: Patient Education ♦ ♦ ♦ ♦ D
- Page 35 and 36: HIV Classification: CDC and WHO Sta
- Page 37 and 38: WHO Clinical Staging of HIV/AIDS an
- Page 39 and 40: Determining Risk of HIV Progression
- Page 41 and 42: CD4 Monitoring and Viral Load Testi
- Page 43 and 44: Table 1. Correlation between CD4 Ce
- Page 45 and 46: Primary HIV Infection Background Pr
- Page 47 and 48: Rapid HIV Testing Background It is
- Page 49: Patient Education In general settin
- Page 52 and 53: 2-2 | Clinical Manual for Managemen
- Page 55 and 56: Nutrition Background Maintaining go
- Page 57 and 58: O: Objective Physical Examination P
- Page 59 and 60: ♦ ♦ Nutrient losses (eg, due to
- Page 61 and 62: Difficulty Chewing or Swallowing or
- Page 63 and 64: Nonoccupational Postexposure Prophy
- Page 65: Once the decision is made to instit
- Page 68 and 69: 2-18 | Clinical Manual for Manageme
- Page 70 and 71: 2-20 | Clinical Manual for Manageme
- Page 72 and 73: 2-22 | Clinical Manual for Manageme
- Page 74 and 75: 2-24 | Clinical Manual for Manageme
- Page 76 and 77: 2-26 | Clinical Manual for Manageme
- Page 78 and 79: 2-28 | Clinical Manual for Manageme
- Page 80 and 81: 2-30 | Clinical Manual for Manageme
- Page 82 and 83:
2-32 | Clinical Manual for Manageme
- Page 84 and 85:
2-34 | Clinical Manual for Manageme
- Page 86 and 87:
2-36 | Clinical Manual for Manageme
- Page 88 and 89:
2-38 | Clinical Manual for Manageme
- Page 90 and 91:
2-40 | Clinical Manual for Manageme
- Page 92 and 93:
2-42 | Clinical Manual for Manageme
- Page 95 and 96:
Section 2—Health Maintenance and
- Page 97 and 98:
Antiretroviral Therapy Background P
- Page 99 and 100:
Initiating Therapy: DHHS ARV Guidel
- Page 101 and 102:
Table 1. Initial Antiretroviral Reg
- Page 103 and 104:
Responding to Apparent Treatment Fa
- Page 105 and 106:
ARV treatment in resource-limited s
- Page 107 and 108:
Adherence Background For HIV-infect
- Page 109 and 110:
adherence, such as mental health is
- Page 111 and 112:
Appendix 1. Scales to Assess Adhere
- Page 113 and 114:
Resistance Testing Background As of
- Page 115:
Resistance Testing in Patients with
- Page 118 and 119:
3-22 | Clinical Manual for Manageme
- Page 120 and 121:
3-24 | Clinical Manual for Manageme
- Page 122 and 123:
3-26 | Clinical Manual for Manageme
- Page 124 and 125:
3-28 | Clinical Manual for Manageme
- Page 126 and 127:
3-30 | Clinical Manual for Manageme
- Page 128 and 129:
3-32 | Clinical Manual for Manageme
- Page 130 and 131:
3-34 | Clinical Manual for Manageme
- Page 132 and 133:
3-36 | Clinical Manual for Manageme
- Page 135 and 136:
Care of HIV-Infected Pregnant Women
- Page 137 and 138:
social services for food, housing,
- Page 139 and 140:
Table 2. Recommended Evaluation and
- Page 141 and 142:
Special Considerations for OI Proph
- Page 143 and 144:
Hyperbilirubinemia Women who are ta
- Page 145 and 146:
Patient Education ♦ ♦ ♦ ♦
- Page 147 and 148:
Section 3—Antiretroviral Therapy
- Page 149 and 150:
Abnormalities of Body-Fat Distribut
- Page 151 and 152:
Pharmacologic Measures Recombinant
- Page 153 and 154:
Dyslipidemia Background In HIV-infe
- Page 155 and 156:
Table 2. Classification of Triglyce
- Page 157 and 158:
Table 3. Drug Treatments for Lipid
- Page 159 and 160:
Patient Education ♦ ♦ ♦ Revie
- Page 161 and 162:
Insulin Resistance and Hyperglycemi
- Page 163:
Patient Education ♦ ♦ ♦ ♦
- Page 166 and 167:
4-18 | Clinical Manual for Manageme
- Page 168 and 169:
4-20 | Clinical Manual for Manageme
- Page 170 and 171:
4-22 | Clinical Manual for Manageme
- Page 172 and 173:
4-24 | Clinical Manual for Manageme
- Page 174 and 175:
4-26 | Clinical Manual for Manageme
- Page 176 and 177:
4-28 | Clinical Manual for Manageme
- Page 178 and 179:
4-30 | Clinical Manual for Manageme
- Page 180 and 181:
4-32 | Clinical Manual for Manageme
- Page 182 and 183:
4-34 | Clinical Manual for Manageme
- Page 184 and 185:
4-36 | Clinical Manual for Manageme
- Page 186 and 187:
Anemia Background Anemia is usually
- Page 188 and 189:
Check the testosterone level in ind
- Page 190 and 191:
Diarrhea Background Diarrhea is a c
- Page 192 and 193:
P: Plan Diagnostic Evaluation For s
- Page 194 and 195:
Ear, Nose, Sinus, Mouth Background
- Page 196 and 197:
Mouth and Throat The oral cavity is
- Page 198 and 199:
Esophageal Problems Background Esop
- Page 200:
References ♦ ♦ ♦ ♦ Dieteric
- Page 203 and 204:
5-18 | Clinical Manual for Manageme
- Page 206 and 207:
Fatigue Background Fatigue is defin
- Page 208:
Patient Education ♦ ♦ ♦ ♦
- Page 211 and 212:
5-26 | Clinical Manual for Manageme
- Page 213 and 214:
5-28 | Clinical Manual for Manageme
- Page 215 and 216:
5-30 | Clinical Manual for Manageme
- Page 218 and 219:
Nausea and Vomiting Background Naus
- Page 220:
♦ ♦ ♦ Lorazepam (Ativan) may
- Page 223 and 224:
5-38 | Clinical Manual for Manageme
- Page 225 and 226:
5-40 | Clinical Manual for Manageme
- Page 227 and 228:
5-42 | Clinical Manual for Manageme
- Page 230 and 231:
Vaginitis/Vaginosis Background Vagi
- Page 232 and 233:
Treatment: Alternative regimens ♦
- Page 234 and 235:
Anal Dysplasia Background Anal canc
- Page 236:
Patient Education ♦ ♦ ♦ Women
- Page 239 and 240:
6-6 | Clinical Manual for Managemen
- Page 242 and 243:
Candidiasis, Vulvovaginal Backgroun
- Page 244:
Patient Education ♦ ♦ ♦ ♦
- Page 247 and 248:
6-14 | Clinical Manual for Manageme
- Page 250 and 251:
Cryptococcal Disease Background Cry
- Page 252:
up to 30 mL of CSF to lower the ICP
- Page 255 and 256:
6-22 | Clinical Manual for Manageme
- Page 258 and 259:
Cytomegalovirus Disease Background
- Page 260 and 261:
CMV retinitis Treatment consists of
- Page 262 and 263:
Dermatologic Staphylococcal Infecti
- Page 264:
Known or suspected MSSA SSTI Treat
- Page 267 and 268:
6-34 | Clinical Manual for Manageme
- Page 269 and 270:
6-36 | Clinical Manual for Manageme
- Page 271 and 272:
6-38 | Clinical Manual for Manageme
- Page 273 and 274:
6-40 | Clinical Manual for Manageme
- Page 275 and 276:
6-42 | Clinical Manual for Manageme
- Page 277 and 278:
6-44 | Clinical Manual for Manageme
- Page 279 and 280:
6-46 | Clinical Manual for Manageme
- Page 282 and 283:
Herpes Zoster/Shingles Background S
- Page 284 and 285:
Histoplasmosis Background Histoplas
- Page 286:
Patient Education ♦ ♦ ♦ ♦ H
- Page 289 and 290:
6-56 | Clinical Manual for Manageme
- Page 291 and 292:
6-58 | Clinical Manual for Manageme
- Page 293 and 294:
6-60 | Clinical Manual for Manageme
- Page 295 and 296:
6-62 | Clinical Manual for Manageme
- Page 297 and 298:
6-64 | Clinical Manual for Manageme
- Page 299 and 300:
6-66 | Clinical Manual for Manageme
- Page 301 and 302:
6-68 | Clinical Manual for Manageme
- Page 303 and 304:
6-70 | Clinical Manual for Manageme
- Page 305 and 306:
6-72 | Clinical Manual for Manageme
- Page 308 and 309:
Section 6—Disease-Specific Treatm
- Page 310 and 311:
Table 1. World Health Organization
- Page 312:
Table 3. Monitoring for Toxicity Si
- Page 315 and 316:
6-82 | Clinical Manual for Manageme
- Page 318 and 319:
Pelvic Inflammatory Disease Backgro
- Page 320 and 321:
Table 1. Treatment Regimens for Pel
- Page 322 and 323:
Pneumocystis Pneumonia Background P
- Page 324 and 325:
Table 1. Standard and Alternative P
- Page 326 and 327:
Progressive Multifocal Leukoencepha
- Page 328 and 329:
Seborrheic Dermatitis Background Se
- Page 330 and 331:
Sinusitis Background Sinusitis is d
- Page 332 and 333:
Syphilis Background Syphilis is a s
- Page 334 and 335:
Treponemal antibody tests (TP-PA [T
- Page 336:
Some patients retain reactive (low-
- Page 339 and 340:
6-106| Clinical Manual for Manageme
- Page 341 and 342:
6-108| Clinical Manual for Manageme
- Page 343 and 344:
6-110| Clinical Manual for Manageme
- Page 345 and 346:
6-112| Clinical Manual for Manageme
- Page 347 and 348:
6-114| Clinical Manual for Manageme
- Page 349 and 350:
6-116| Clinical Manual for Manageme
- Page 351 and 352:
6-118| Clinical Manual for Manageme
- Page 353 and 354:
6-120| Clinical Manual for Manageme
- Page 355 and 356:
6-122| Clinical Manual for Manageme
- Page 357 and 358:
Pain Syndrome and Peripheral Neurop
- Page 359 and 360:
Pharmacologic interventions The fol
- Page 361 and 362:
Patient Education ♦ ♦ ♦ ♦
- Page 363 and 364:
Palliative Care and HIV Background
- Page 365 and 366:
GASTROINTESTINAL Nausea, vomiting
- Page 367:
Advance Care Planning Advance care
- Page 370 and 371:
8-2 | Clinical Manual for Managemen
- Page 373 and 374:
Depression Background Major depress
- Page 375 and 376:
of symptoms. The risk of recurrence
- Page 377 and 378:
Panic Disorder Background Panic dis
- Page 379:
♦ If benzodiazepines are used, th
- Page 382 and 383:
8-14 | Clinical Manual for Manageme
- Page 384 and 385:
8-16 | Clinical Manual for Manageme
- Page 386 and 387:
8-18 | Clinical Manual for Manageme
- Page 388 and 389:
8-20 | Clinical Manual for Manageme
- Page 390 and 391:
9-2 | Clinical Manual for Managemen
- Page 392 and 393:
9-4 | Clinical Manual for Managemen
- Page 395 and 396:
Sulfa Desensitization Background Tr
- Page 397 and 398:
Patient Education Background It has
- Page 399 and 400:
Web-Based Resources Background The